Abstract Submissions

Overview

Conference attendees are invited to submit abstracts on topics pertaining to precision medicine, pharmacogenomics, pharmacovigilance, practice, innovation, and/or research. Submitted abstracts can be considered for a poster presentation during the conference.

Abstracts accepted as posters will be on display with a poster viewing session during the evening reception to allow attendees to network and discuss strategies with authors.

Important Dates

Date Event
July 25, 2022 Online abstract submission opens
August 25, 2022 11:59 p.m. EDT Deadline to submit an abstract(s)
September 9, 2022 Acceptance/rejection communicated

Abstract Type/Category

Submissions are encouraged for topics related to research and innovation in precision medicine, including but not limited to the following areas:

  • Pharmacogenomics
  • Pharmacovigilance
  • Cancer genomics
  • Genomics education
  • Bioinformatics
  • Genomics in the electronic health record
  • Genomic laboratory testing
  • Clinical implementation of genomics
  • Genomics patient case presentations*

*Patient cases should focus on pharmacogenomics, pharmacovigilance, or precision medicine interventions and solutions in clinical care. All patient information should be de-identified in strict compliance with Health Insurance Portability and Accountability Act (HIPAA) rules and specifics of the case and/or patient should be omitted and/or altered as appropriate to ensure HIPAA compliance.

Encore presentations are allowed.

Abstract Submission and Review

Abstracts should be submitted online by 11:59 p.m. on August 25th, 2022

All completed and eligible abstracts will be made available to the reviewers for review and scoring, with final decisions to be made by the Program Committee by September 9th 2022. Incomplete abstracts will not be reviewed. Contributed abstracts sessions provide a forum in which to share practice information, disseminate research findings, and educate colleagues.

Abstracts accepted as posters will be on display September 28, 2022, with a poster viewing session during the evening reception to allow attendees to network and discuss strategies with authors. Abstracts accepted as podium presentations will be presented in a rapid-fire oral presentation session on September 29th.

Responsibilities of the Presenting Author

The first author listed for each abstract serves as the presenting author and as the primary contact for correspondence regarding the abstract. All authors will be asked to confirm that they are submitting their abstract with the intent of attending the “Updates in Precision Medicine: Pharmacogenomics and Pharmacovigilance” conference and that each co-author has been informed of this abstract submission and has agreed to all information as it was submitted.

Poster Session

2020 Post Presentation

Accepted abstracts will be scheduled for an open poster session during the “Updates in Precision Medicine: Pharmacogenomics and Pharmacovigilance” conference . The purpose of the Poster session is to encourage conference attendees and speakers to informally discuss current projects, research, and innovations in precision medicine with colleagues.

Rapid-Fire Oral Podium Session

Abstract presenters can indicate interest in a podium presentation on September 29th, 2022 at the time of submission. Four posters will be selected to present. In this session, presenters will have 5 to 10 minutes to present and summarize their findings with a brief time for questions/discussion. Although patient cases are eligible for poster presentation, preference will be given to podium presentations focusing on original science.

Format

  • Abstracts of original science – Content should be structured into the following four (4) sections
    • Background:
    • Methods:
    • Results:
    • Conclusions:
  • Clinical cases – Content should be structured into the following four (4) sections:
    • Clinical Presentation:
    • Imaging Findings:
    • Role of Imaging in Patient Care:
    • Summary/Discussion Points:
  • Tables/Graphics – The use of high-quality tables and graphics are encouraged if they are relevant to the research submitted. Each abstract may include up to (3) graphics and/or tables. The submission site supports both .gif and .jpg graphic formats.
  • 500-word limit

Do not include:

  • References, key words, credits, or grant support in your submission.
  • Names or personal information of any patient participating in the study or trial. If you do, the abstract will not be considered for presentation.

Brought to you by:

Cop logo